The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
That said, we are doing a clinical trial right now with a molecule called MIB 636. MIB is just Metro Biotech. And that's a couple of clinical trials that are being done at Brigham and Women's Hospital in Boston, separate group for me, it's all independent. And that's just a safety study.
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.